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Cloning of the Gene Containing Mutations
that Cause PARK8-Linked Parkinson’s Disease
ern world and presents as a progressive movement
disorder. The hallmark pathological features of PD are
loss of dopaminergic neurons from the substantia ni-
Coro Paisa´n-Ruı´z,1,11 Shushant Jain,2,3,11
E. Whitney Evans,4 William P. Gilks,3 Javier Simo´n,1
Marcel van der Brug,5 Adolfo Lo´pez de Munain,6,7
Silvia Aparicio,1 Angel Martı´nez Gil,8 gra and neuronal intracellular Lewy body inclusions.
Naheed Khan,3 Janel Johnson,4 Parkinsonism is typically sporadic in nature; however,
Javier Ruiz Martinez,9 David Nicholl,10 several rare familial forms are linked to genetic loci,
Itxaso Marti Carrera,7 Amets Sae´nz Penˇa,6 and the identification of causal mutations has provided
Rohan de Silva,3 Andrew Lees,3 insight into the disease process. PARK8, identified in
Jose´ Fe´lix Martı´-Masso´,7 Jordi Pe´rez-Tur,1,* 2002 by Funayama and colleagues, appears to be a
Nick W. Wood,2,* and Andrew B. Singleton4,* common cause of familial PD. We describe here the
1Unitat de Gene`tica Molecular cloning of a novel gene that contains missense muta-
Departament de Geno`mica i Proteo`mica tions segregating with PARK8-linked PD in five fami-
Institut de Biomedicina de Vale`ncia-CSIC lies from England and Spain. Because of the tremor
E46010 Vale`ncia observed in PD and because a number of the families
Spain are of Basque descent, we have named this protein
2 Department of Molecular Neuroscience dardarin, derived from the Basque word dardara,
Institute of Neurology meaning tremor.
Queen Square
London WCIN 3BG Introduction
United Kingdom
3 Reta Lila Weston Institute of Neurological Studies Parkinson’s disease (PD) is a severe, progressive, neuro-
Windeyer Building degenerative disorder characterized clinically by tremor,
46 Cleveland Street bradykinesia, rigidity, and postural instability. The dis-
London W1T 45F ease is diagnosed postmortem by pallor of the substan-
United Kingdom tia nigra pars compacta and the presence of brainstem
4 Molecular Genetics Unit Lewy bodies. While current therapies alleviate the motor
5 Cell Biology and Gene Expression Unit symptoms of PD, they are largely palliative.
National Institute on Aging The identification of rare familial forms of parkinson-
National Institutes of Health ism and subsequent cloning of causal genetic mutations
Porter Neuroscience Research Center has had significant impact on our understanding of the
Room 1A1000 molecular mechanisms underlying typical PD. The dis-
35 Lincoln Drive covery of mutations in genes encoding -synuclein
Bethesda, Maryland 20892 (Polymeropoulos et al., 1997), parkin (Kitada et al., 1998),6 Unidad Experimental DJ-1 (Bonifati et al., 2003), and PINK1 (Valente et al.,7 Servicio de Neurologı´a 2004) has provided a basis for much of the ongoing
Hospital Donostia
molecular work in the PD field and facilitates disease
Paseo del Dr Begiristain, s/n
modeling and the design and testing of targeted thera-
E20014 San Sebastia´n
peutics. Each new gene implicated in the etiology of PD
Spain
sheds light on the disease process; hence, there is much8 Hospital Ntra. Sra. de la Antigua
interest in the identification of novel gene mutations.
Zuma´rraga
In 2002, linkage of PD in a large family with apparentlyE20700 Guipu´zkoa
autosomal dominant disease was ascribed to a 13.6cMSpain
region at chromosome 12p11.2-q13.1 containing ap-9 Hospital de Mendaro
proximately 116 genes and given the name PARK8 (Fu-E20850 Guipu´zkoa
nayama et al., 2002). This linkage was independentlySpain
replicated, and to date eight families have been convinc-10Birmingham Department of Neurology
ingly associated with this locus (Funayama et al., 2002;Queen Elizabeth Hospital
N.K., S.J., N. Pavese, J. Holton, L.H. Eunson, M.G.Birmingham B15 2TH
Sweeney, W.P.G., J. Vaughan, J. Gayton, G. Lennox, T.United Kingdom
Revesz, A.B.S., D.N., D. Brooks, A.L., P. Piccini, M.B.
Davis, and N.W.W., unpublished; C.P.-R., A.S.P.,
A.L.d.M., I.M.C., A.M.G., J.F.M.-M., J.P.-T., unpublished;Summary
Zimprich et al., 2004).
While most PARK8 families described possess a clini-Parkinson’s disease (PD; OMIM #168600) is the second
cal phenotype of typical PD, the pathological findingsmost common neurodegenerative disorder in the West-
range from pure nigral degeneration in the absence of
Lewy body pathology as noted in the Sagamihara kin-*Correspondence: jpereztur@ibv.csic.es (J.P.-T.), nwood@ion.ucl.
dred (Funayama et al., 2002) to typical Lewy body PDac.uk (N.W.W.), singleta@mail.nih.gov (A.B.S.)
11These authors contributed equally to this work. in the British family, PL (N.K., S.J., N. Pavese, J. Holton,
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Table 1. Markers Used to Fine-Map the Candidate Interval and Determine Interfamily Shared Haplotype and the Boundaries of This Haplotype
The black outline indicates the extent of the haplotype common between each Basque family.
a Phase not determined.
b Within KIF21A.
c Within DKFZp434H111.
L.H. Eunson, M.G. Sweeney, W.P.G., J. Vaughan, J. Gay- K543R (Basque allele frequency 0.01), segregating with
disease in three apparently unrelated Basque familieston, G. Lennox, T. Revesz, A.B.S., D.N., D. Brooks, A.L.,
P. Piccini, M.B. Davis, and N.W.W., unpublished). A third (UGM003, UGM005, and UGM006) (C.P.-R., A.S.P.,
A.L.d.M., I.M.C., A.M.G., J.F.M.-M., J.P.-T., unpublished)family, the Western Nebraska kindred, with suggestive
linkage to PARK8, showed a wide range of clinical and but absent from the fourth PARK8-linked Basque family
we were studying, UGM004. Given the rarity of this vari-pathological phenotypes (Wszolek et al., 2004).
We have previously identified four families from the ant, these data suggested that UGM003, UGM005, and
UGM006 are ancestrally related and could be used toBasque region of Spain and a family from the United
Kingdom that each showed positive linkage to the determine a minimal interkindred disease haplotype. In
the first instance, we chose to type SNPs betweenPARK8 locus (N.K., S.J., N. Pavese, J. Holton, L.H. Eun-
son, M.G. Sweeney, W.P.G., J. Vaughan, J. Gayton, G. D12S331 and D12S1668 in order to verify that there was
indeed a common haplotype among the three familiesLennox, T. Revesz, A.B.S., D.N., D. Brooks, A.L., P. Pic-
cini, M.B. Davis, and N.W.W., unpublished; C.P.-R., and in the hope that these data would limit this haplotype
further. We identified a variant (rs10876410) that de-A.S.P., A.L.d.M., I.M.C., A.M.G., J.F.M.-M., J.P.-T., un-
published). Using these families, we undertook a me- limited the critical interval on the p arm of the disease
haplotype shared by these three families (Table 1). How-thodical assessment of candidate genes in an attempt
to identify the underlying genetic lesion responsible ever, more importantly, we demonstrated that all four
Basque families we were studying shared a smaller dis-for disease.
ease haplotype, consisting of 15 SNPs and one microsa-
tellite and delimited by flanking markers rs4548690 andResults
D12S1653. This reduced the critical disease interval to
2.6 Mb, a region that contains only 11 genes and pre-In the course of sequencing the kinesin gene KIF21A as
a candidate for PARK8 disease, we identified a SNP, dicted transcripts (Figure 1).
Dardarin Mutations in PARK8 PD
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Figure 1. Ideogram of PARK8 Candidate Region
(A) Ideogram of chromosome 12 showing the linked areas defined by Funayama et al. in 2002, the refined area reported here, and the region
shared by all four Basque families.
(B) Schematic representation of the known genes and predicted transcripts in the area shared by the Basque families. In red, the putative
transcript where mutations in PARK8-linked families were identified.
We undertook a systematic sequence analysis of In order to assess the prevalence of these two muta-
tions in PD patients, we examined 137 Basque PD pa-these genes and predicted open reading frames in af-
fected members of the four Basque families and in a tients (30 with a family history and 107 sporadic cases)
and 94 PD patients from North America with a positivefifth large family from the UK, kindred PL. We identified
segregating mutations within a putative kinase domain- family history for disease. We did not identify the Y1654C
mutation in any patients. We identified 11 Spanish PDcontaining transcript, DKFZp434H2111, which we chose
to call PARK8. PARK8 is a 9 kb predicted transcript, patients, 10 Basque, who carried the R1396G mutation;
of these, 6 had a positive family history for PD.which contains a 7449 bp open reading frame encoding
a 2482 amino acid protein that includes a leucine-rich We proceeded to verify that this gene is expressed in
brain. Analysis of the multitissue Northern blots probedrepeat, a kinase domain, a RAS domain, and a WD40
domain (Figure 2). We identified a variant R1396G that with a sequenced PCR product spanning both mutation
sites indicated the presence of a 9 kb transcript (Figuresegregates with disease in all four Basque families and
a variant Y1654C in the same gene that segregates with 4) in all tissue types examined. These data also show
that this gene is expressed throughout the adult humandisease in family PL (Figures 2 and 3). We failed to
identify either of these variants in 1300 chromosomes brain but at a lower level than in heart and liver. We
successfully amplified overlapping cDNA fragmentsfrom North American controls and 160 chromosomes
from Basque controls. across the predicted 9 kb transcript (Figure 5).
Figure 2. Mutations in Dardarin that Are Linked to PARK8 PD
(A) Schematic of dardarin structure.
(B) Mutations R1396G and Y1654C are indicated by black arrowheads. Human dardarin protein aligned with other orthologs from rat (XP_235581),
mouse (BAC28700), chicken (XP_425418), and tetraodon (CAG05593). Amino acid number is based on the human protein.
(C) Chromatograms showing mutant sequence (top) and wild-type sequence (bottom) of R1396G (left) and Y1654C (right).
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8% of a series of 137 apparently unrelated Basque PD
cases. As is the case in most dominant genetic diseases,
the mutations we describe here alter residues that are
conserved across species, with the exception of the
R1396 residue, which is an alanine in Tetraodon nigrovi-
ridis.
We have identified seven affected mutation-positive
family members in kindred PL and seven unaffected
members who do not carry the mutation. These data
support the view that this variant is 100% penetrant
in this family. In the Basque pedigrees excluding all
unaffected family members below the maximum ob-
served age at onset of 79 years, the penetrance of this
mutation is also 100%. These data contrast with the
70% penetrance originally observed in the Sagamihara
kindred (Funayama et al., 2002).
The data presented here suggest that R1396G is a
relatively common cause of PD in the Basque popula-
tion, accounting for approximately 8% of disease in the
series we examined. Furthermore, our data indicate that
Figure 3. PARK8-Linked Pedigrees this mutation can result in a late-onset disease, which
UGM003, UGM004, UGM005, and UGM006 originate from the can reduce the apparent familiality of this form, as mu-
Basque region; kindred PL was collected in the United Kingdom. tation carriers may die before manifesting or being
WT indicates a mutation-negative subject, M indicates a subject diagnosed with the signs and symptoms of PD. This is
carrying a heterozygous mutation (R1396G UGM003, UGM004,
highlighted by the fact that five of the identified 1396G-UGM005, and UGM006; Y1654C Family PL). Gender has been
positive PD cases presented in the absence of a familymasked to protect the anonymity of the families. Currently unaf-
history for disease. Although the proportion of casesfected mutation carriers have not been shown; in all instances these
individuals have not yet reached the maximum age at onset ob- carrying this mutation may be high because of a founder
served. effect in a relatively isolated population, it is reasonable
to suspect that other sporadic cases in the general pop-
ulation will also harbor PARK8 mutations.
Discussion The phenotype noted in the Basque and British fami-
lies is remarkably similar. The mean age at onset is
We provide here data that implicates mutations in the around 65 years and there is a benign course with excel-
novel protein dardarin as a cause of PARK8 PD. This is lent response to low doses of L-Dopa; furthermore, the
supported by four pieces of genetic evidence; first, we majority of patients in the British and Basque families
have identified two missense mutations segregating present with unilateral leg or hand tremor and the ab-
with disease in five families previously linked to PARK8, sence of cognitive impairment.
a total of 26 mutation-positive affected family members; Our analyses suggest that PARK8 is expressed
second, with the exception of LOC441636 (which is simi- throughout the adult brain. Although this gene appears
lar to submaxillary apomucin and thus a gene unlikely expressed at higher levels in other tissues, this is not
to play a role in neurodegeration), we have sequenced unusual for genes that cause neurodegenerative dis-
every known gene and predicted transcript in the candi- eases (Li et al., 1995). Based on Northern blot data, the
date region, as defined by the minimal interfamily haplo- major mutation-containing transcript is the 9 kb species,
type shared by the Basque kindreds (Table 1), and the although our data indicate that there may be some addi-
gene encoding dardarin was the only gene that con- tional alternative splicing in this gene. Three other pieces
tained variants not identified in the general population; of evidence support the presence of a 9 kb transcript:
third, these mutations are not present in 1300 North first, there are numerous overlapping ESTs and cDNA
American control and 160 Basque control chromo- clones extending across the predicted mRNA and these
clones and ESTs overlap by multiple exons; second,somes; and fourth, we identified the 1396G mutation in
Figure 4. Northern Blot Analysis of Dardarin
Multiple tissue Northern blots (BD Biosci-
ences) probed for dardarin with a 1 kb probe
amplified across the two exons that contain
mutations. Blot A: lane 1, heart; lane 2, brain
(whole); lane 3, placenta; lane 4, lung; lane 5,
liver; lane 6, skeletal muscle; lane 7, kidney;
lane 8, pancreas. Blot B is a multiregion brain
blot: lane 1, cerebellum; lane 2, cerebral cor-
tex; lane 3, medulla; lane 4, spinal cord; lane
5, occipital pole; lane 6, frontal lobe; lane 7,
temporal lobe; lane 8, putamen. A major tran-
script of 9 kb was identified (black arrowhead)
in addition to minor smaller transcripts.
Dardarin Mutations in PARK8 PD
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Figure 5. Predicted Transcript Based on Alignment of Multiple Human Multiexon ESTs and Fully Sequenced Human cDNA Clones
The most informative overlapping clones and ESTs are shown. Tiled blue lines represent overlapping fragments successfully amplified from
cDNA isolated from M17 neuroblastoma cells and from a brain marathon-ready cDNA library (BD Biosciences).
Experimental Proceduresorthologous proteins with identical domain structures
and of equivalent length are predicted in Mus musculus
Candidate Gene Sequencing(Caenepeel et al., 2004), Rattus norvegicus (XP_235581),
Genomic primer design for all genes was performed using Exon-
and Tetraodon nigroviridis (CAG05593); and third, we Primer (http://ihg.gsf.de/ihg/ExonPrimer.html). Each exon and at
have successfully amplified overlapping cDNA frag- least 50 bp of flanking intronic sequence was PCR amplified using
primer pairs listed (available upon request) from genomic DNA. PCRments across the transcript.
amplification was carried out using Qiagen taq polymerase, and 10Although the function of dardarin is unknown, the
pmol of both forward and reverse primers as per the manufacturer’sstructure suggests that this protein is probably a cyto-
instructions (Qiagen Inc, CA). In the first instance, DNA from twoplasmic kinase. Indeed, using a bioinformatic approach,
affected, disease haplotye-carrying members of each family was
PARK8, along with a similar predicted gene, LRRK1, used. Any variants of interest were then assessed for segregation
was previously mapped as a tyrosine kinase-like (TKL) in the remaining family members. Each product was sequenced
using forward and reverse primers with Applied Biosystems BigDyeprotein (Manning et al., 2002). Because phosphorylation
terminator v3.1 sequencing chemistry as per the manufacturer’sof proteins has been implicated in the pathogenesis of
directions. The resulting reactions were run on an ABI3100 geneticneurodegenerative disease, it is particularly tempting to
analyzer and analyzed with Sequencher software (Genecodes, VA).hypothesize a role for dardarin in the phosphorylation
of proteins central to PD, such as -synuclein and Tau.
SNP Analyses
Taking this into account, the description of myriad In order to assess the extent of the interkindred disease haplotype,
PARK8 pathological phenotypes ranging from pure ni- SNPs were selected from dbSNP between markers D12S331 and
gral degeneration to pathologies with varied protein de- D12S1668. SNPs were selected from dbSNP, choosing those veri-
fied variants that were likely to be informative. SNPs were genotypedposition, including synucleinopathy and tauopathy, is
by PCR amplification and direct sequencing. All available familyintriguing and these data raise the possibility that dar-
members of the Basque kindreds were typed for these SNPs indarin may present a link between these key molecules.
order to maximize our ability to obtain phase.
Some care must be exercised here; no conclusions
about these described pathologies can be made until
Mutation Assay
each examined case is shown to possess mutations Mutations R1396G and Y1654C were assessed in 650 North Ameri-
and the prevailing pathology is shown to be above and can control subjects, 80 Basque control subjects, 94 North American
beyond that observed in normal aging. In three common PD cases with a positive family history of PD, and 137 Spanish PD
cases with and without a family history of PD. To identify the R1396Gneurodegenerative diseases, i.e., Alzheimer’s disease,
mutation, a genomic fragment was amplified using primer pairHuntington’s disease, and PD, dominant mutations oc-
DKFZp434 30F 5-TCAACAGGAATGTGAGCAGG-3 and DKFZp434cur in genes that encode the predominant deposited
30R 5-CCCACAATTTTAAGTGAGTTGC-3. The resulting 386 bp
protein species (Chartier-Harlin et al., 1991; Huntington fragment was digested with BstUI at 37C overnight and electropho-
Group, 1993; Polymeropoulos et al., 1997; Singleton et resed on a 2% agarose gel containing ethidium bromide. The prod-
al., 2004). The exceptions to this rule are presenilins 1 ucts were assessed by UV visualization. The presence of the 1396G
mutation resulted in an uncut full-length product of 386 bp, whereasand 2 (Rogaev et al., 1995; Sherrington et al., 1995),
the wild-type fragment cuts to produce 72 bp and 314 bp bands.where mutations occur in proteins that are involved in
A mutation-positive assay result was confirmed by sequencing asthe processing of the deposited species. Analogy might
described above. There was no restriction assay readily available
suggest that dardarin is involved in the processing, ex- for the 1654C mutation so the genomic fragment was PCR amplified
pression, or clearance of -synuclein. as described above from each sample using primer pair DKFZp434
In summary, we present here compelling evidence 34F 5-CATTTGCTCAACAAGGTTGG-3 and DKFZp434 34R 5-ATG
CCATCTCCCTAATTTCTC-3 and sequenced as described above.implicating mutations in a novel gene containing a leu-
cine-rich repeat, kinase domain, RAS domain, and WD40
Northern Blotdomain as the first genetic cause of late-onset familial
A 1011 bp probe that covered both mutation containing exonsand sporadic PD. We have named this gene PARK8 and
was generated from cDNA template using 20 pmol of primersthe protein dardarin. These data will impact not only
CDNAex29F 5-GAGCATTGTACCTTGCTGTC-3 and CDNAEx34R
patients and their families but will open novel avenues 5-GACAATAAGCTTCAGGAGACC-3 and the expand high-fidelity
of research aimed at identifying and ultimately halting PCR system as per the manufacturer’s instructions (Roche Diagnos-
tics, CA). The resulting product was gel excised, labeled withthe molecular events that lead to PD.
Neuron
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[-32P]dCTP, and column purified using standard protocols. The Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A.,
Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997).labeled probe was hybridized to multitissue Northern blots (BD Bio-
sciences, CA) as per the manufacturer’s instructions. Following me- Mutation in the alpha-synuclein gene identified in families with Par-
kinson’s disease. Science 276, 2045–2047.dium stringency washing, the blots were exposed to phosphor
screens overnight and an image captured the next day on a Rogaev, E.I., Sherrington, R., Rogaeva, E.A., Levesque, G., Ikeda,
Storm phosphorimager. M., Liang, Y., Chi, H., Lin, C., Holman, K., and Tsuda, T. (1995).
Familial Alzheimer’s disease in kindreds with missense mutations
cDNA Amplification in a gene on chromosome 1 related to the Alzheimer’s disease type
Total RNA was extracted from an M17 neuroblastoma cell line, and 3 gene. Nature 376, 775–778.
first strand synthesis of cDNA was performed with oligo dT priming Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque,
using Superscript III as per the manufacturer’s instructions (In- G., Ikeda, M., Chi, H., Lin, C., Li, G., and Holman, K. (1995). Cloning
vitrogen, CA). The resulting cDNA and cDNA from a marathon RACE of a gene bearing missense mutations in early-onset familial Alzhei-
ready adult human brain library (BD Biosciences) was used as tem- mer’s disease. Nature 375, 754–760.
plate to amplify overlapping fragments of the predicted 9 kb tran-
Singleton, A., Myers, A., and Hardy, J. (2004). The law of mass action
script. Overlapping primers within each exon were designed using
applied to neurodegenerative disease: a hypothesis concerning the
Generunner (http://www.generunner.com), and PCR was carried out
etiology and pathogenesis of complex diseases. Hum. Mol. Genet.
using the Qiagen taq polymerase kit and 10 pmol of both forward
13, R123–R126.
and reverse primers as per the manufacturer’s instructions (Qiagen).
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The HUGO Gene Nomenclature Committee (http://www.gene.ucl.
ac.uk/nomenclature/) has updated the name of this gene to LeucineReceived: October 15, 2004
Rich Repeat Kinase 2, gene symbol LRRK2. The gene name PARK8Revised: October 20, 2004
will be removed from usage upon publication of this manuscript.Accepted: October 20, 2004
The protein name will remain dardarin.Published online: October 22, 2004
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